Compare AstraZeneca plc (AZN) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Matson Inc — how do they compare? AstraZeneca plc trades at $166.76 (market cap $253.13B), while Matson Inc trades at $210.44 (market cap $6.38B). The key difference: AstraZeneca plc is far larger — about 39.7× Matson Inc's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | MATX | |
|---|---|---|
Market Cap | $253.13B | $6.38B |
Sector | Health | Technology |
52-Week High | $209.48 | $210.95 |
52-Week Low | $137.44 | $88.05 |
Enterprise Value | $279.37B | $6.98B |
Dividend Yield | 1.92% | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Matson (MATX) trades at $205.15, up 0.19% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 12.92% net income margin and consistent earnings beats in recent quarters. Recent developments include a dividend increase to $0.38 per share and progress on its LNG-powered vessel construction program, highlighting operational strength and shareholder returns.
The outlook for MATX is positive, supported by niche Pacific shipping routes and resilient earnings. Key opportunities include growth in expedited China service and share repurchases. Risks involve exposure to trade volatility and potential margin pressure from higher costs. Analyst consensus is bullish with 64% buy ratings, but investors should monitor global trade flows and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
